Reportlinker Adds Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Bone Metastases Therapeutics market. The report identifies the key trends shaping and driving the global Bone Metastases Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bone Metastases Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Bone Metastases Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Bone Metastases Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Bone Metastases Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Bone Metastases Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Bone Metastases Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Bone Metastases Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Bone Metastases Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Bone Metastases Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Bone Metastasis Therapeutics: Introduction 6
2.1 Disease Overview 6
2.2 Epidemiology 7
2.3 Etiology and Pathophysiology 8
2.4 Signs and Symptoms 10
2.5 Diagnosis 11
2.6 Treatment and Management Pattern: 13
2.6.1 Systemic Therapy: 13
2.6.2 External Beam Radiation Therapy 14
2.7 GlobalData Pipeline Report Guidance 15
3 Bone Metastases Therapeutics: Market Characterization 16
3.1 Bone Metastases Therapeutics Market Size (2005-2010) – Global 16
3.2 Bone Metastases Therapeutics Market Forecast (2010-2017) – Global 17
3.3 Bone Metastases Therapeutics Market Size (2005-2010) – The US 18
3.4 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The US 19
3.5 Bone Metastases Therapeutics Market Size (2005-2010) – France 20
3.6 Bone Metastases Therapeutics Market Forecasts (2010-2017) – France 21
3.7 Bone Metastases Therapeutics Market Size (2005-2010) – Germany 22
3.8 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Germany 23
3.9 Bone Metastases Therapeutics Market Size (2005-2010) – Italy 24
3.10 Bone Metastases Therapeutics Market Forecast (2010-2017) – Italy 25
3.11 Bone Metastases Therapeutics Market Size (2005-2010) – Spain 26
3.12 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Spain 27
3.13 Bone Metastases Therapeutics Market Size (2005-2010) – The UK 28
3.14 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The UK 29
3.15 Bone Metastases Therapeutics Market Size (2005-2010) – Japan 30
3.16 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Japan 31
3.17 Drivers and Barriers for the Bone Metastases Therapeutics Market 32
3.17.1 Drivers for the Bone Metastases Therapeutics Market 32
3.17.2 Barriers for the Bone Metastases Therapeutics Market 32
3.18 Opportunity and Unmet Need Analysis 32
3.19 Key Takeaway 33
4 Bone Metastases Therapeutics: Competitive Assessment 34
4.1 Overview 34
4.2 Strategic Competitor Assessment 34
4.3 Product Profiles for the Major Marketed Products in the Bone Metastases Therapeutics Market 35
4.3.1 Zometa (Zoledronate) 35
4.3.2 Xgeva (denosumab) 36
4.3.3 Bondronat (ibandronic acid) 37
4.4 Key Takeaway 37
5 Bone Metastases Therapeutics: Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Bone Metastases Therapeutics Pipeline – Pipeline by Phases of Development 38
5.3.1 Bone Metastases Therapeutics – Phase III Pipeline 38
5.3.2 Bone Metastases Therapeutics – Phase II Pipeline 39
5.3.3 Bone Metastases Therapeutics – Phase I Pipeline 39
5.3.4 Bone Metastases Therapeutics – Preclinical Pipeline 39
5.3.5 Technology Trends Analytic Framework 40
5.4 Bone Metastases Therapeutics Market – Clinical Pipeline by Mechanism of Action 41
5.5 Bone Metastases Therapeutics – Promising Drugs Under Clinical Development 42
5.6 Molecule Profile for Promising Drugs Under Clinical Development 43
5.6.1 Alpharadin (radium-223 chloride) 43
5.6.2 Orazol (Zoledronic acid) 43
5.7 Key Takeaway 44
6 Bone Metastases Therapeutics: Clinical Trials Mapping 45
6.1 Clinical Trials by Country (US, EU and Japan) 45
6.2 Clinical Trials by Phase 46
6.3 Clinical Trials by Trial Status 47
6.4 Prominent Sponsors 48
6.5 Top Companies Participating in Bone Metastases Therapeutics Clinical Trials 50
7 Bone Metastases Therapeutics: Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Bone Metastases Therapeutics: Implications for Future Market Competition 52
8 Bone Metastases Therapeutics: Future Players 53
8.1 Introduction 53
8.2 Company Profiles 54
8.2.1 Novartis AG 54
8.2.2 Amgen Inc. 60
8.2.3 Bayer AG 63
8.2.4 Algeta ASA 67
8.2.5 Merrion Pharmaceuticals Plc 69
8.2.6 Other Companies in the Bone Metastases Therapeutics Market 70
9 Bone Metastases Therapeutics: Licensing and Partnership Deals 72
10 Bone Metastases Therapeutics: Appendix 76
10.1 Market Definitions 76
10.2 Abbreviations 76
10.3 Research Methodology 77
10.3.1 Coverage 77
10.3.2 Secondary Research 77
10.3.3 Forecasting 78
10.3.4 Primary Research 80
10.3.5 Expert Panel Validation 80
10.4 Contact Us 80
10.5 Disclaimer 80
10.6 Bibliography 81
1.1 List of Tables
Table 1: Metastatic Bone Disease is Prevalent in Many Types of Cancer 6
Table 2: Prevalence of Bone Metastases in Different Cancer Types, 2010 7
Table 3: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010 16
Table 4: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017 17
Table 5: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010 20
Table 6: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017 21
Table 7: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010 22
Table 8: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017 23
Table 9: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010 24
Table 10: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017 25
Table 11: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010 26
Table 12: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017 27
Table 13: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010 28
Table 14: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29
Table 15: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010 30
Table 16: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017 31
Table 17: Bone Metastases Therapeutics – Phase III Pipeline, 2010 38
Table 18: Bone Metastases Therapeutics – Phase II Pipeline, 2010 39
Table 19: Bone Metastases Therapeutics – Phase I Pipeline, 2010 39
Table 20: Bone Metastases Therapeutics – Preclinical Pipeline, 2010 39
Table 21: Bone Metastases Therapeutics – Most Promising Drugs Under Clinical Development, 2010 42
Table 22: Bone Metastases Therapeutics – Clinical Trials by Country, 2011 45
Table 23: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011 46
Table 24: Bone Metastases Therapeutics - Clinical Trials by Status, 2011 47
Table 25: Bone Metastases Therapeutics - Prominent Sponsors, 2011 49
Table 26: Bone Metastases Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Table 27: Novartis – Oncology Pipeline, 2010 56
Table 28: Novartis Deals, 2009-2010 57
Table 29: Amgen Inc. – Bone Metastases, Pipeline, 2010 61
Table 30: Amgen Inc. Deals, 2009-2010 62
Table 31: Bayer AG – Oncology Pipeline, 2010 64
Table 32: Bayer AG Deals, 2009-2010 65
Table 33: Algeta ASA Pharmaceuticals – Oncology, Pipeline, 2010 68
Table 34: Algeta ASA Pharmaceuticals – Bone Metastases, Pipeline, 2010 68
Table 35: Algeta ASA Deals, 2009-2010 68
Table 36: Merrion Pharmaceuticals – Oncology Pipeline, 2010 69
Table 37: Merrion Pharmaceuticals – Oncology Pipeline, 2010 69
Table 38: Merrion AG Deals, 2009-2010 70
Table 39: Bone Metastases Pain Therapeutics Market – Future Players 70
Table 40: Bone Metastases Therapeutics, Global, Deals 72
1.2 List of Figures
Figure 1: (a) Osteolytic lesions; (b) Osteoblastic lesion 7
Figure 2: Mechanism of Tumor Metastasis to Bone 8
Figure 3: Prevalence of Skeletal-Related Events in Patients with Metastatic Bone Disease not Treated with Bisphosphonates 9
Figure 4: Diagnosis of Bone Metastases 11
Figure 5: Algorithm for Imaging for Cancer Patients in the US 12
Figure 6: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010 16
Figure 7: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017 17
Figure 8: Bone Metastases Therapeutics Market, The US, Revenue ($m), 2005–2010 18
Figure 9: Bone Metastases Therapeutics Market, The US, Forecasts ($m), 2010–2017 19
Figure 10: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010 20
Figure 11: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017 21
Figure 12: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010 22
Figure 13: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017 23
Figure 14: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010 24
Figure 15: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017 25
Figure 16: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010 26
Figure 17: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017 27
Figure 18: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010 28
Figure 19: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29
Figure 20: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010 30
Figure 21: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017 31
Figure 22: Opportunity and Unmet Need in the Bone Metastases Therapeutics Market 33
Figure 23: Bone Metastases Therapeutics – Strategic Competitor Assessment, 2010 34
Figure 24: Bone Metastases Therapeutics – Pipeline by Phase of Development, 2010 38
Figure 25: Bone Metastases Therapeutics – Technology Trends Analytics Framework, 2010 40
Figure 26: Bone Metastases Therapeutics – Technology Trends Analytics Framework – Description, 2010 40
Figure 27: Bone Metastases Therapeutics – Pipeline by Mechanism of Action, 2010 41
Figure 28: Bone Metastases Therapeutics – Clinical Trials by Country, 2011 45
Figure 29: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011 46
Figure 30: Bone Metastases Therapeutics - Clinical Trials by Status, 2011 47
Figure 31: Bone Metastases Therapeutics - Overall Sponsors, 2011 48
Figure 32: Bone Metastases Therapeutics - Prominent Sponsors, 2011 48
Figure 33: Bone Metastases Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Figure 34: Bone Metastases Therapeutics Market, Drivers and Restraints, 2011 51
Figure 35: Implications for Future Market Competition in Bone Metastases, 2011 52
Figure 36: Bone Metastases Therapeutics – Pipeline by Company, 2011 53
Figure 37: GlobalData Market Forecasting Model 79Novartis AG
Amgen Inc.
Bayer AG
Algeta ASA
Merrion Pharmaceuticals Plc
To order this report:
: Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Contact:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article